

Thomas Damgaard Sandahl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2302210/publications.pdf>

Version: 2024-02-01

54
papers

1,290
citations

430442

18
h-index

377514

34
g-index

58
all docs

58
docs citations

58
times ranked

1749
citing authors

#	ARTICLE	IF	CITATIONS
1	Soluble <sc>CD</sc>163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 173-180.	1.9	132
2	Incidence and mortality of alcoholic hepatitis in Denmark 1999-2008: A nationwide population based cohort study. <i>Journal of Hepatology</i> , 2011, 54, 760-764.	1.8	130
3	Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS. <i>Gut</i> , 2011, 60, 1389-1393.	6.1	111
4	The Prevalence of Wilson's Disease: An Update. <i>Hepatology</i> , 2020, 71, 722-732.	3.6	103
5	Hepatic Macrophage Activation and the LPS Pathway in Patients With Alcoholic Hepatitis: A Prospective Cohort Study. <i>American Journal of Gastroenterology</i> , 2014, 109, 1749-1756.	0.2	81
6	A soluble form of the macrophage-related mannose receptor (MR/CD206) is present in human serum and elevated in critical illness. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 453-461.	1.4	79
7	Increased levels of circulating Th17 cells in quiescent versus active Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 248-255.	0.6	50
8	Validation of prognostic scores for clinical use in patients with alcoholic hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 1127-1132.	0.6	45
9	Short-term and Long-term Causes of Death in Patients With Alcoholic Hepatitis in Denmark. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1739-1744.e1.	2.4	44
10	Time-dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct-acting antiviral therapy of chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2020, 27, 28-35.	1.0	36
11	The macrophage activation marker <sc>CD</sc>163 combined with markers of the Enhanced Liver Fibrosis (<sc>ELF</sc>) score predicts clinically significant portal hypertension in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1222-1231.	1.9	34
12	Single-centre experience of the macrophage activation marker soluble (s)CD163 - associations with disease activity and treatment response in patients with autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 1062-1070.	1.9	33
13	The soluble mannose receptor (sMR) is elevated in alcoholic liver disease and associated with disease severity, portal hypertension, and mortality in cirrhosis patients. <i>PLoS ONE</i> , 2017, 12, e0189345.	1.1	32
14	Highest Frequencies of Interleukin-22-Producing T Helper Cells in Alcoholic Hepatitis Patients with a Favourable Short-Term Course. <i>PLoS ONE</i> , 2013, 8, e55101.	1.1	26
15	Cytotoxic T lymphocytes and natural killer cells display impaired cytotoxic functions and reduced activation in patients with alcoholic hepatitis. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 308, G269-G276.	1.6	25
16	Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 986-993.	0.6	23
17	Intravenous and oral copper kinetics, biodistribution and dosimetry in healthy humans studied by [⁶⁴ Cu]copper PET/CT. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2020, 5, 15.	1.8	21
18	Circulating mannan-binding lectin, M α C, L α C, H α C, ficolin and collectin-1 levels in patients with acute liver failure. <i>Liver International</i> , 2015, 35, 756-763.	1.9	20

#	ARTICLE	IF	CITATIONS
19	Changes in adipokines after transjugular intrahepatic porto-systemic shunt indicate an anabolic shift in metabolism. <i>Clinical Nutrition</i> , 2012, 31, 940-945.	2.3	17
20	Mass spectrometry characterization of circulating human serum albumin microheterogeneity in patients with alcoholic hepatitis. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 122, 141-147.	1.4	16
21	The damage-associated molecular pattern HMGB1 is elevated in human alcoholic hepatitis, but does not seem to be a primary driver of inflammation. <i>Apmis</i> , 2016, 124, 741-747.	0.9	15
22	The pathophysiology of Wilson's disease visualized: A human 64Cu PET study. <i>Hepatology</i> , 2022, 75, 1461-1470.	3.6	15
23	No Effect in Alcoholic Hepatitis of Gut-Selective, Broad-Spectrum Antibiotics on Bacterial Translocation or Hepatic and Systemic Inflammation. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00306.	1.3	12
24	Designing Clinical Trials in Wilson's Disease. <i>Hepatology</i> , 2021, 74, 3460-3471.	3.6	12
25	Psychometric methods for diagnosing and monitoring minimal hepatic encephalopathy – current validation level and practical use. <i>Metabolic Brain Disease</i> , 2022, 37, 589-605.	1.4	12
26	Blood culture-positive infections in patients with alcoholic hepatitis. <i>Scandinavian Journal of Infectious Diseases</i> , 2014, 46, 902-905.	1.5	11
27	Metformin Stimulates Intestinal Glycolysis and Lactate Release: A single-Dose Study of Metformin in Patients With Intrahepatic Portosystemic Stent. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1329-1336.	2.3	11
28	Liver-related effects of chronic hepatitis C antiviral treatment. <i>World Journal of Gastroenterology</i> , 2020, 26, 2931-2947.	1.4	11
29	Bis-choline tetrathiomolybdate prevents copper-induced blood-brain barrier damage. <i>Life Science Alliance</i> , 2022, 5, e202101164.	1.3	11
30	Tumor necrosis factor- α acutely up-regulates urea synthesis in vivo in rats – a hepatic component of inflammatory catabolism?. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2010, 70, 151-157.	0.6	10
31	Computing the Pathogenicity of Wilson's Disease ATP7B Mutations: Implications for Disease Prevalence. <i>Journal of Chemical Information and Modeling</i> , 2019, 59, 5230-5243.	2.5	10
32	Effects of insulin-like growth factor-1 administration on <i>in vivo</i> regulation of urea synthesis in normal subjects and patients with cirrhosis. <i>Liver International</i> , 2011, 31, 132-137.	1.9	9
33	The lectin pathway of the complement system is downregulated in Crohn's disease patients who respond to anti-TNF- α therapy. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 521-528.	0.6	9
34	Extracellular vesicle-associated soluble CD163 and CD206 in patients with acute and chronic inflammatory liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 588-596.	0.6	9
35	Randomised clinical study: acute effects of metformin versus placebo on portal pressure in patients with cirrhosis and portal hypertension. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 320-328.	1.9	9
36	Alcoholic hepatitis. <i>Danish Medical Journal</i> , 2014, 61, B4755.	0.5	9

#	ARTICLE	IF	CITATIONS
37	Low Interleukin-22 Binding Protein Is Associated With High Mortality in Alcoholic Hepatitis and Modulates Interleukin-22 Receptor Expression. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00197.	1.3	8
38	High hepatic macrophage activation and low liver function in stable Wilson patients - a Danish cross-sectional study. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 169.	1.2	7
39	Combination of radiofrequency ablation with transarterial chemoembolization for treatment of hepatocellular carcinoma: experience from a Danish tertiary liver center. <i>Acta Radiologica</i> , 2016, 57, 844-851.	0.5	6
40	Decreased monocyte shedding of the migration inhibitor soluble CD18 in alcoholic hepatitis. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e160.	1.3	6
41	The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson's disease. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 173.	1.2	6
42	ATP7B variant spectrum in a French pediatric Wilson disease cohort. <i>European Journal of Medical Genetics</i> , 2021, 64, 104305.	0.7	6
43	Cognitive impairment in stable Wilson disease across phenotype. <i>Metabolic Brain Disease</i> , 2021, 36, 2173-2177.	1.4	4
44	Diminished Non-Classical Monocytes in the Blood Associate with Disease Severity in Alcoholic Hepatitis. <i>Clinical and Experimental Gastroenterology</i> , 2021, Volume 14, 259-267.	1.0	3
45	Highly Increased Levels of Interleukin-1 Inhibitor Heavy Chain 4 (ITIH4) in Autoimmune Cholestatic Liver Diseases. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 796-802.	0.7	3
46	Early normalization of reduced urea synthesis capacity after direct-acting antiviral therapy in hepatitis C cirrhosis. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 319, G151-G156.	1.6	2
47	Soluble CD163 (sCD163): Biomarker of Kupffer Cell Activation in Liver Disease. <i>Biomarkers in Disease</i> , 2016, , 1-28.	0.0	2
48	Changes in the Levels of Mannan-Binding Lectin and Ficolins During Head-Down Tilted Bed Rest. <i>Aviation, Space, and Environmental Medicine</i> , 2014, 85, 805-811.	0.6	1
49	The long-term prognosis of alcoholic hepatitis is poor and independent of disease severity for patients surviving an acute episode. <i>Journal of Hepatology</i> , 2018, 68, 1330-1331.	1.8	1
50	Soluble CD163 (sCD163): Biomarker of Kupffer Cell Activation in Liver Disease. <i>Biomarkers in Disease</i> , 2017, , 321-348.	0.0	1
51	The galactose elimination capacity test to monitor liver disease course in patients with Wilson's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2022, , 1-6.	0.6	1
52	Editorial: measuring inflammatory and fibrotic components of portal hypertension - a non-invasive hepatic venous pressure gradient? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 205-206.	1.9	0
53	Interferon lambda 4 genotype and pathway in alcoholic hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 304-311.	0.6	0
54	Editorial: metformin for portal hypertension - old dog, new tricks? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 347-347.	1.9	0